Lapatinib – Targeted Cancer Therapy

Lapatinib is a potent targeted anti-cancer medication belonging to the group of tyrosine kinase inhibitors (TKIs). It is a unique small-molecule compound capable of simultaneously targeting two key receptors responsible for cancer cell growth and division.

The mechanism of action involves the reversible inhibition of the intracellular tyrosine kinase domains of both EGFR (ErbB1) and HER2 (ErbB2) receptors. Unlike monoclonal antibodies that bind to the extracellular portion of the receptor, lapatinib penetrates the cell to block signaling from within. This results in cell cycle arrest and apoptosis of tumor cells that overexpress HER2. This dual inhibition provides a more effective suppression of tumor growth and helps overcome resistance to therapies that target only one receptor type.

Administered orally, lapatinib is frequently used in combination with other chemotherapeutic agents or endocrine therapy.

Wikipedia page

Indications

Lapatinib is indicated for the treatment of adult patients in the following clinical scenarios:

HER2-positive Breast Cancer: advanced or metastatic breast cancer overexpressing HER2, in combination with capecitabine (following progression on trastuzumab).
Hormone Receptor-Positive Breast Cancer: in combination with an aromatase inhibitor (e.g., letrozole) for postmenopausal women with metastatic disease.
Combination Therapy: may also be used in combination with trastuzumab for patients with progressive disease.

Dosage and administration

Lapatinib dosage depends on the specific treatment regimen and concomitant medications.

With Capecitabine: the standard dose is 1250 mg (five tablets) taken once daily continuously.
With Letrozole: the standard dose is 1500 mg (six tablets) taken once daily.
Administration Rules: must be taken at least 1 hour before or 1 hour after a meal. The full daily dose should be taken at once.
Restrictions: avoid grapefruit juice, as it significantly increases the drug’s concentration in the blood.
Dose Modification: if severe toxicity occurs (e.g., diarrhea or rash), the dose may be temporarily reduced or interrupted.

The use of lapatinib is restricted in the following cases:

Hypersensitivity: known allergic reactions to lapatinib or any of its excipients.
Cardiac Impairment: pre-existing conditions with a significantly decreased left ventricular ejection fraction (LVEF).
Pregnancy and Lactation: potential for fetal harm; breastfeeding is prohibited during therapy.
Hepatic Impairment: use with extreme caution in patients with severe liver dysfunction; dose reduction is required.

Common adverse reactions associated with lapatinib therapy include:

Gastrointestinal: diarrhea (very common; can lead to dehydration), nausea, and vomiting.
Dermatologic: hand-foot syndrome, acneiform rash, and dry skin.
Hepatic: hepatotoxicity (elevation of liver enzymes and bilirubin; regular monitoring is mandatory).
Cardiac: risk of decreased LVEF and QT interval prolongation.
Respiratory: risk of interstitial lung disease (ILD) or pneumonitis (rare).

Frequently Asked Questions

Lapatinib is a potent tyrosine kinase inhibitor with a dual mechanism of action. It simultaneously blocks two types of receptors both on the surface and inside the cells: EGFR (ErbB1) and HER2 (ErbB2). By interrupting the signaling pathways these receptors use to trigger growth and division, lapatinib effectively slows tumor progression.

Lapatinib is primarily indicated for the treatment of advanced or metastatic breast cancer that overexpresses the HER2 protein. It is typically used in combination with other agents, such as capecitabine or trastuzumab, especially in cases where prior therapy has ceased to be effective.

Lapatinib can affect the heart's pumping ability (decreased left ventricular ejection fraction) and cause hepatotoxicity (liver damage). Patients require regular echocardiograms and blood tests for liver enzymes. Immediate medical attention is needed if severe fatigue, yellowing of the skin, or swelling occurs.

Lapatinib should be taken either 1 hour before or 1 hour after a meal. It is crucial to maintain a consistent administration routine every day, as food—particularly high-fat meals—significantly increases drug absorption, which can unpredictably intensify side effects.

Diarrhea and skin rash are the most frequently reported side effects. Diarrhea can be severe and lead to dehydration, making it vital to start antidiarrheal treatment and increase fluid intake at the first sign. The skin rash often resembles acne and should be managed with physician-recommended moisturizers.